MX2012007933A - Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. - Google Patents

Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Info

Publication number
MX2012007933A
MX2012007933A MX2012007933A MX2012007933A MX2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A
Authority
MX
Mexico
Prior art keywords
methods
topical transdermal
transdermal dexmedetomidine
dexmedetomidine compositions
compositions
Prior art date
Application number
MX2012007933A
Other languages
English (en)
Spanish (es)
Inventor
Geraldine A Henwood
Randall J Mack
Christopher T Sharr
John J Koleng Jr
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of MX2012007933A publication Critical patent/MX2012007933A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012007933A 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. MX2012007933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29344010P 2010-01-08 2010-01-08
PCT/US2011/020462 WO2011085162A2 (en) 2010-01-08 2011-01-07 Topical transdermal dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012007933A true MX2012007933A (es) 2012-08-15

Family

ID=44306157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007933A MX2012007933A (es) 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Country Status (10)

Country Link
US (1) US20130072532A1 (enExample)
EP (1) EP2521544A4 (enExample)
JP (1) JP2013516482A (enExample)
CN (1) CN102753169A (enExample)
AU (1) AU2011204315A1 (enExample)
CA (1) CA2786598A1 (enExample)
MX (1) MX2012007933A (enExample)
NZ (2) NZ703808A (enExample)
RU (1) RU2012133969A (enExample)
WO (1) WO2011085162A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
EP2994120B1 (en) * 2013-05-06 2019-10-09 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
RU2646512C2 (ru) * 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
CN105764495A (zh) * 2013-10-07 2016-07-13 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
KR101891185B1 (ko) * 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20190060007A (ko) * 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CN107929234B (zh) * 2017-12-25 2021-07-23 温州医科大学附属第一医院 一种应用于烧伤创面修复的外用制剂膏体
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
KR20220002950A (ko) 2019-05-01 2022-01-07 클렉시오 바이오사이언시스 리미티드 소양증의 치료 방법
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
CN113577556A (zh) * 2021-08-01 2021-11-02 武汉左点科技有限公司 一种用于阴道康复治疗的生物反馈电刺激方法及装置
WO2024037545A1 (zh) * 2022-08-17 2024-02-22 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Also Published As

Publication number Publication date
CN102753169A (zh) 2012-10-24
CA2786598A1 (en) 2011-07-14
JP2013516482A (ja) 2013-05-13
WO2011085162A2 (en) 2011-07-14
EP2521544A4 (en) 2013-08-21
AU2011204315A1 (en) 2012-08-02
WO2011085162A3 (en) 2011-11-17
NZ601195A (en) 2015-02-27
NZ703808A (en) 2016-01-29
EP2521544A2 (en) 2012-11-14
RU2012133969A (ru) 2014-02-20
US20130072532A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
MX344521B (es) Aminas heterociclicas y sus usos.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
EP4647076A3 (en) Therapeutically active compounds and their methods of use
EP4249001A3 (en) Topical gels
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
SG10201700125VA (en) Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof
GB201111485D0 (en) Drug composition and its use in therapy
PL2632452T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
EP3054931A4 (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
IL251543B (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
EP2897621A4 (en) COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP3449917A3 (en) Tapentadol for preventing chronification of pain
DK2155179T3 (da) Axomadol til smertebehandling arthrose
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal